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currence.  Results: The median time from RC to recurrence 
and the median OS after recurrence was 10.9 and 5.4 months, 
respectively. Neither the time to recurrence nor the type of 
recurrence (systematic vs. local) was predictive of the OS. In 
contrast, age (hazard ratio (HR) 1.53, p = 0.011), lymph node 
metastasis (HR 1.56, p = 0.007), and positive surgical margins 
(HR 1.53, p = 0.046) significantly affected the OS after disease 
recurrence. In addition, the dichotomized Charlson comor-
bidity index (CCI; dichotomized into >2 vs. 0–2) was the only 
comorbidity score with an independent prediction of OS (HR 
1.41, p = 0.033). We observed a significant gain in the base 
model’s predictive accuracy, i.e. from 68.4 to 70.3% (p < 
0.001), after inclusion of the dichotomized CCI.  Conclusions: 
We present the first outcome study of comorbidity indices 
used as predictors of OS after disease recurrence in patients 
undergoing RC for UCB. The CCI at the time of RC had no sig-
nificant influence on the time to recurrence but represented 
an independent predictor of OS after disease recurrence. 
 © 2014 S. Karger AG, Basel 
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 Abstract 
 Objective: To identify prognostic clinical and histopatholog-
ical parameters, including comorbidity indices at the time of 
radical cystectomy (RC), for overall survival (OS) after recur-
rence following RC for urothelial carcinoma of the bladder 
(UCB).  Materials and Methods: A retrospective multicenter 
study was carried out in 555 unselected consecutive patients 
who underwent RC with pelvic lymph node dissection for 
UCB from 2000 to 2010. A total of 227 patients with recur-
rence comprised our study group. Cox proportional hazards 
regression models were calculated with established vari-
ables to assess their independent influence on OS after re-
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 Introduction 
 Radical cystectomy (RC) with pelvic lymph node dis-
section constitutes the gold standard treatment for muscle-
invasive urothelial carcinoma of the bladder (UCB) and 
high-risk non-muscle-invasive disease refractory to instil-
lation therapy  [1, 2] . Despite this aggressive treatment, 
subsequent disease recurrence occurs in approximately 
half of patients with muscle-invasive bladder cancer in the 
first 24 months after RC  [1, 3] . Over two thirds of patients 
with disease recurrence die within 1 year of recurrence  [4, 
5] . Various clinicopathological parameters have been iden-
tified as predictors of overall survival (OS) in patients who 
experience disease recurrence after RC  [4] . In particular, 
systemic inflammatory parameters, symptoms at recur-
rence, and a shorter time to recurrence have been described 
to be independent predictors of OS after recurrence  [4–7] .
 Comorbidity is an important independent prognostic 
factor for outcome prediction in patients with several on-
cological diseases  [8] . Evidence exists that comorbidity 
indices predict the cancer-independent survival and the 
90-day mortality after RC  [9, 10] . The Eastern Coopera-
tive Oncology Group (ECOG) performance status has 
been described as a predictor of the OS after disease re-
currence following RC  [7] .
 The aim of our multicenter study was to analyze the 
performance of the most commonly used comorbidity 
 indices [Adult Comorbidity Evaluation-27 (ACE-27), 
Charlson comorbidity index (CCI), ECOG performance 
status, and American Society of Anesthesiologists (ASA) 
score] defined at the time of RC in order to predict the 
oncological outcome in UCB patients who experience 
disease recurrence after RC.
 Patients and Methods 
 Study Population 
 This was an institutional review board-approved study. This 
retrospective study included 555 unselected consecutive patients 
who underwent RC with pelvic lymph node dissection for muscle-
invasive or recurrent high-risk non-muscle-invasive UCB without 
distant metastases at 2 tertiary urological centers between 2000 and 
2010. In total, 227 patients experienced disease recurrence con-
firmed by imaging studies (CT, MRI, and/or bone scan) and/or 
histological verification. RC and bilateral pelvic lymph node dis-
section were performed by several surgeons. No patient underwent 
neoadjuvant chemotherapy and/or radiotherapy.
 Comorbidity and Performance Indices 
 Five indices were assessed at the time of RC: ASA, ACE-27, 
CCI, age-adjusted CCI (ACCI), and ECOG as described previous-
ly  [9, 10] . The ASA score was obtained prospectively by anesthesi-
ologists in both institutions. According to the current literature, all 
indices were dichotomized for better clinical applicability in the 
following manner: ASA, 1–2 versus 3–4; ECOG, 0–1 versus 2–3; 
CCI, 0–2 versus >2; ACCI, 0–5 versus >5, and ACE-27, 0–1 versus 
2–3 as well as 0–2 versus 3. The CCI, ACCI, and ACE-27 were cal-
culated without taking UCB into account  [8–10] .
 Outcome Measures 
 The study goals were to examine the OS after disease recur-
rence and to determine the individual predictive accuracy (PA) 
gain in the aforementioned comorbidity scores in multivariable 
outcome models. Early recurrence was defined as tumor recur-
rence within 12 months after RC. The type of recurrence was clas-
sified as local or distant disease  [5, 6] . The time of death was veri-
fied by local cancer registries and by the treating physician. The 
histological parameters used for univariable and multivariable 
analyses were soft tissue surgical margin (STSM), lymphovascular 
invasion (LVI), and concomitant carcinoma in situ (CIS). All sur-
gical specimens were processed according to standard pathological 
procedures and evaluated by experienced genitourinary patholo-
gists at each institution. The tumor stage was assigned according 
to the 7th edition of the TNM classification (2009)  [11] . The his-
topathological grade was based on the 1973 WHO classification. 
Since all of the study patients had undifferentiated grading, this 
criterion was not considered in the analysis. A positive surgical 
margin was defined when tumor was present in the inked areas of 
the RC specimen, with the exception of tumor presence at urethral 
and ureteral margins. LVI was defined as tumor cells in an endo-
thelium-lined space without discrimination between L1 and V1. If 
any disagreement regarding pathological specimens was observed, 
the original histopathology report was rereviewed by independent 
pathologists. For better clinical practicability, age was dichoto-
mized with a cutoff at 75 years, which is the most applied cutoff 
age in patients undergoing RC  [12, 13] . Follow-up regimens after 
RC were conducted according to institutional protocols and fol-
lowing current guidelines. Patients were seen every 3–4 months for 
the first year after RC, every 6 months during years 2–5, and an-
nually thereafter. Diagnostic imaging of the abdomen and/or up-
per tracts and chest radiography were performed at least annually 
or when clinically indicated.
 Statistical Analyses 
 Continuous metric variables are reported as medians with in-
terqurtile range (IQR). Pertinent characteristics of early and late 
recurrence were compared. The Wilcoxon-Mann-Whitney test 
was used for nonnormally distributed continuous variables and 
comparisons between categorical variables were made using Fish-
er’s exact test and a χ 2 test.
 OS rates after recurrence were estimated using the Kaplan-
Meier method. The log-rank test was employed to compare sur-
vival curves. Univariable and multivariable Cox proportional haz-
ards regression analyses were performed to assess the influence of 
several clinical parameters (including 5 comorbidity and perfor-
mance indices, age, and BMI) and pathological parameters. For 
this purpose, a multivariable Cox regression model was created 
using the stepwise backward elimination process. To assess the 
PA of the various comorbidity indices, the inclusion of a comor-
bidity index in a base model (without integration of comorbidity 
scores) was used. Assessment of the AUC values (c-indices) for 
estimation of the PA according to Harrell et al.  [14] was performed. 
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 Table 1.  Demographic data classified by time of recurrence (≤12 vs. >12 months) after RC in 227 recurrent patients with UCB
Variables Entire cohort
(n = 227)
Early recurrencea
(n = 171; 75.3%)
Late recurrenceb
(n = 56; 24.7%)
p value
Recurrence side
Local
Systemic
36 (15.9)
191 (84.1)
21 (16.3)
108 (83.7)
15 (15.3)
83 (84.7)
0.842
Age at RC
<75 years
≥75 years
153 (67.4)
74 (32.6)
83 (64.3)
46 (35.7)
70 (71.4)
28 (28.6)
0.259
Median age at RC (IQR), years 71 (63–76) 72 (65–78) 68.5 (60–75) 0.024
Median BMI (IQR), kg/m2 26 (24–28.3) 25.7 (23.5–27.9) 26.2 (24.8–29.0) 0.315
Gender
Male
Female
178 (78.4)
49 (21.6)
94 (72.9)
35 (27.1)
84 (85.7)
14 (14.3)
0.020
ECOG
0
1
2
3
53 (23.3)
122 (53.7)
44 (19.4)
8 (3.5)
29 (22.5)
65 (50.4)
28 (21.7)
7 (5.4)
24 (24.5)
57 (58.2)
16 (16.3)
1 (1.0)
0.202
ASA
1
2
3
39 (17.2)
106 (46.7)
82 (36.1)
24 (18.6)
55 (42.6)
50 (38.8)
15 (15.3)
51 (52.0)
32 (32.7)
0.371
ACE-27
0
1
2
3
40 (17.6)
53 (23.3)
82 (36.1)
52 (22.9)
25 (19.4)
25 (19.4)
44 (34.1)
35 (27.1)
15 (15.3)
28 (28.6)
38 (38.8)
17 (17.3)
0.158
CCI
0–1
2–3
4–5
≥6–7
54 (23.8)
141 (62.1)
30 (13.2)
2 (0.8)
30 (23.3)
75 (58.1)
22 (17.1)
2 (1.6)
24 (24.5)
66 (67.4)
8 (8.1)
0 (0.0)
0.421
CCI
0–2
>2
139 (61.2)
88 (38.8)
78 (60.5)
51 (39.5)
61 (62.2)
37 (37.8)
0.785
ACCI
0–3
4–5
6–7
8–11
24 (10.6)
101 (44.5)
64 (28.2)
7 (3.1)
26 (20.2)
55 (42.6)
41 (31.8)
7 (5.5)
29 (29.5)
46 (47.0)
23 (23.5)
0 (0.0)
0.224
Clinical tumor stage
<cT3 and cN0
>cT2 and/or cN+
159 (70)
68 (30)
83 (64.3)
46 (35.7)
76 (77.6)
22 (22.4)
0.031
Presence of LVI in RC specimens 142 (62.6) 91 (70.5) 51 (52.0) 0.004
Presence of CIS in RC specimens 106 (46.7) 54 (41.9) 52 (53.1) 0.094
Presence of STSM in RC specimens 33 (14.5) 25 (19.4) 8 (8.2) 0.018
pN status
pN0
pN+
130 (57.3)
97 (42.7)
67 (51.9)
62 (48.1)
63 (64.3)
35 (35.7)
0.062
pT stage at RC
pT0
pTa
pTis
pT1
pT2
pT3
pT4
17 (7.5)
1 (0.4)
10 (4.4)
21 (9.3)
39 (17.2)
96 (42.3)
43 (18.9)
11 (8.5)
1 (0.8)
3 (2.3)
4 (3.1)
15 (11.6)
64 (49.6)
31 (24.0)
6 (6.1)
0 (0.0)
7 (7.1)
17 (17.3)
24 (24.5)
32 (32.7)
12 (12.2)
<0.001
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The c-indices of the base model with and without the respective 
comorbidity index were compared according to the Mantel-
Haenszel test  [15] .
 The reported p values are 2-sided, and p < 0.05 was considered 
statistically significant. Data were analyzed using SPSS 19.0 (IBM 
Corp., N.Y., USA).
 Results 
 Study Population 
 The demographic characteristics of 227 study patients 
with recurrence after RC and their distribution in relation 
to the time point of recurrence are shown in  table 1 . The 
median time from RC to recurrence was 10.9 months (IQR 
5–24). The median age at the time of RC was 71.0 years 
(IQR 63–76). Patients with early recurrence ( ≤ 12 months) 
after RC were older at RC (p = 0.024), had a higher clinical 
tumor stage (p = 0.031), had higher rates of LVI (p = 0.004), 
and had higher positive margin rates (p = 0.018) in their 
RC specimens. Females made up a higher proportional 
percentage of the patients suffering an early versus a late 
recurrence (27 vs. 14%, respectively; p = 0.020). There was 
no varied distribution between the early- and late-recur-
rence subgroups for all assessed comorbidity indices. In 
particular, the dichotomized CCI was not associated with 
early or late recurrence of UCB after RC (p = 0.785). On 
the other hand, patients with a CCI of 0–2 had significant-
ly lower systemic recurrence rates compared to patients 
with CCI >2 (79.1 and 92.0%, respectively; p = 0.009).
 Univariable Analyses Predicting OS after Recurrence 
 The median OS after recurrence was 5.4 months. After 
6, 12, 36, and 60 months, 37.4, 21.1, 5.7, and 0.4% of the 
entire study group were alive, respectively. Neither the 
time to recurrence nor the location of recurrence was a 
significant predictor of OS after disease recurrence (p = 
0.806 and p = 0.108, respectively;  fig. 1 a, b). The dichoto-
mized CCI (>2 vs. 0–2) was a significant predictor of OS 
in the univariable analysis (HR 1.53, 95% CI 1.13–2.07, 
p = 0.006;  table 2 ). In particular, patients with a CCI of 
0–2 showed an OS after 6, 12, 36, and 60 months of 44.6, 
26.6, 7.2, and 0.7%, respectively. In contrast, patients with 
a CCI >2 showed an OS of 26.1, 12.5, 3.4, and 1.1%, re-
spectively (p = 0.003;  fig. 1 c). Details of the univariable 
analyses of OS after recurrence are listed in  table  2 . In 
particular, neither the kind of recurrence (systemic vs. lo-
cal) nor the time of recurrence (cutoff 12 months) showed 
significant differences in survival. Along with the afore-
mentioned dichotomized CCI results, the dichotomized 
ACCI (0–5 vs. >5, p  = 0.002), continuous ACCI (p < 
0.001), and ACE-27 (0–2 vs. >2, p = 0.036) significantly 
predicted the OS after disease recurrence ( table 2 ).
 Multivariable Analyses Predicting OS after Recurrence 
 The results of the multivariable Cox models are shown 
in  table 3 . According to a stepwise backward elimination 
process, independent predictors of OS after recurrence 
were positive surgical margins (HR 1.53, p = 0.046), pa-
tients older than 75 years (HR 1.53, p  = 0.011), lymph 
node metastasis at RC (HR 1.56, p = 0.007), and CCI >2 
(HR 1.41, p = 0.033). The multivariable model containing 
clinical and histopathological variables with and without 
the dichotomized CCI showed a PA of 70.3 and 68.4%, 
respectively. The PA gain was 1.9% (p < 0.001). Based on 
its predictive strength and the significant gain in PA, only 
the dichotomized CCI was included in the Cox model. 
Other indices were not included as their contribution was 
not significant (data not shown).
 Table 1.  (continued)
Variables Entire cohort
(n = 227)
Early recurrencea
(n = 171; 75.3%)
Late recurrenceb
(n = 56; 24.7%)
p value
pT/pN stage
<pT3 and pN0
>pT2 and/or pN+
68 (30.0)
159 (70.0)
23 (17.8)
106 (82.2)
45 (46.4)
52 (53.6)
<0.001
Adjuvant chemotherapy 84 (37.2) 48 (37.2) 36 (37.1) 0.988
Median lymph nodes removed (IQR), n 14 (10–20) 14 (10–21) 14 (11–18) 0.889
Institution
Regensburg
Bolzano
161 (70.9)
66 (29.1)
122 (71.3)
49 (28.7)
39 (69.6)
17 (30.4)
0.866
Values are presented as numbers (%) unless otherwise stated. a ≤12 months. b >12 months.
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 Discussion 
 In this study, 227 patients who experienced recurrence 
after RC had comorbidity assessment performed at the 
time of RC using 4 validated comorbidity/performance 
indices: ASA, CCI, ECOG, and ACE-27. Systemic recur-
rence occurred in 84% of the study patients, and 3 of 4 
study patients developed recurrence within 1 year after 
RC. Only 6% of the patients were alive 36 months after 
disease recurrence, emphasizing the aggressive nature of 
recurrent UCB. Three main findings emerged from this 
study. Firstly, the CCI was the only comorbidity index 
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 Fig. 1. Kaplan-Meier curves to assess the influence of the kind of 
recurrence (local vs. systemic ( a ), the time to recurrence (>12 vs. 
 ≤ 12 months) ( b ), and the dichotomized CCI (0–2 vs. >2) ( c ) on OS 
after recurrence in patients who underwent RC for UCB. 
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that could increase the PA in a multivariable analysis of 
OS  after disease recurrence. Secondly, the CCI at the time 
of RC had no impact on the time to recurrence but influ-
enced the type of recurrence, with more systemic recur-
rences occurring in patients with higher comorbidity. 
Thirdly, neither the time to recurrence nor the type of 
recurrence was a significant predictor of the OS after dis-
ease recurrence.
 The assessment of comorbidity in predicting survival 
has become increasingly important in oncology  [8] . We 
therefore assessed 4 different indices to evaluate comor-
bidity at the time of RC as a predictor of OS after disease 
recurrence. In the univariable Cox analyses, the continu-
ous and dichotomized ACCI (p < 0.001 and p = 0.002, 
respectively), the dichotomized CCI (p = 0.006), and the 
dichotomized ACE-27 (0–2 vs. 3, p = 0.036) were sig-
nificant predictors of OS after recurrence. In our multi-
variable analysis, only the dichotomized CCI could in-
crease the PA of our Cox model, with a PA gain of 1.9% 
(p < 0.001). To our knowledge, this is the first study to 
show that comorbidity is predictive of OS in this patient 
cohort.
 In our study, no significant differences using comor-
bidity indices were observed in patients experiencing ear-
ly or late recurrence of UCB ( table 1 ). In particular, pa-
tients with early and late recurrences showed no signifi-
cant differences in the distribution of the dichotomized 
CCI (CCI 0–2; 60.5 and 62.2%, respectively; p = 0.785). 
Our outcome results are in contrast to prior studies inves-
tigating patients after recurrence of UCB. In a recent 
study by Rink et al. [4] , a shorter time to recurrence fol-
lowing RC was identified as a risk factor for poor OS after 
recurrence, which could not be demonstrated in our co-
hort. Mitra et al.  [6] showed early recurrence (<12 months) 
 Table 2.  Univariable Cox regression analyses to assess the associa-
tion of clinicopathological variables and OS after recurrence in 
patients who underwent RC for UCB
Variables HR 95% CI p value
Age (cont.) 1.031 1.014–1.048 <0.001
Age ≥75 years (ref. <75 years) 1.529 1.128–2.074 0.006
Female sex (ref. male) 1.104 0.778–1.556 0.579
BMI (cont.) 0.996 0.960–1.033 0.828
ECOG (cont.) 1.173 0.971–1.415 0.098
ECOG 2–3 (ref. 0–1) 1.081 0.769–1.521 0.652
ASA (cont.) 1.233 0.995–1.526 0.055
ASA 3–4 (ref. 1–2) 1.288 0.953–1.741 0.099
ACE-27 (cont.) 1.160 0.997–1.350 0.055
ACE-27 2–3 (ref. 0–1) 1.243 0.920–1.680 0.157
ACE-27 3 (ref. 0–2) 1.443 1.024–2.033 0.036
CCI (cont.) 1.103 0.976–1.248 0.116
CCI >2 (ref. 0–2) 1.528 1.130–2.065 0.006
ACCI (cont.) 1.183 1.076–1.299 <0.001
ACCI >5 (ref. 0–5) 1.636 1.199–2.232 0.002
pN+ stage (ref. pN0) 1.578 1.167–2.133 0.003
Number of lymph nodes 
removed (cont.) 0.982 0.965–0.999 0.041
pT3/4 stage (ref. ≤pT2) 1.533 1.119–2.099 0.008
>pT2 and/or pN+ 
(ref. <pT3, pN0) 1.902 1.337–2.705 <0.001
LVI present (ref. absent) 1.684 1.218–2.328 0.002
CIS present (ref. absent) 0.857 0.637–1.152 0.306
Positive STSM (ref. negative) 1.838 1.226–2.754 0.003
Adjuvant chemotherapy 
(ref. no) 0.967 0.715–1.307 0.825
Systemic recurrence (ref. local) 0.955 0.644–1.415 0.818
Recurrence ≤12 months (ref. 
recurrence >12 months) 1.325 0.918–1.913 0.132
Bolzano (ref. Regensburg) 1.043 0.764–1.425 0.791
cont. = Continuous; ref. = reference; HR = hazard ratio; 95% 
CI = 95% confidence interval.
 Table 3.  Multivariable Cox proportional hazards regression analy-
ses of variables associated with OS after recurrence in patients who 
underwent RC for UCB
Variables  Stepwise backward 
elimination 
HR  (95% CI) p value
Female sex (ref. male) – –
Bolzano (ref. Regensburg) – –
BMI (cont.) – –
Concomitant CIS (ref. absent) – –
Positive STSM (ref. negative) 1.529 (1.007–2.321) 0.046
Number of lymph nodes 
removed (cont.) 0.985 (0.967–1.003) 0.103
Adjuvant chemotherapy (ref. no) – –
Age ≥75 years (ref. <75 years) 1.526 (1.103–2.112) 0.011
pT3/4 stage (ref. ≤pT2) – –
pN+ stage (ref. pN0) 1.562 (1.132–2.156) 0.007
LVI present (ref. absent) – –
Systemic recurrence (ref. local) – –
CCI >2 (ref. CCI 0–2) 1.405 (1.027–1.921) 0.033
Recurrence ≤12 months 
(ref. >12 months) – –
AUCa (with CCI), % (IQR) 70.3 (61.9–78.7)
Gain in predictive accuracy (ref. 
basic model without CCI), % 1.9 <0.001
cont. = Continuous; ref. = reference; AUC = area under the 
curve; HR  = hazard ratio; 95% CI  = 95% confidence interval. 
a Without CCI: 68.4%.
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after RC as an independent predictor of OS after recur-
rence. Additionally, they assessed the location of recur-
rence and found distant metastasis and the combination 
of distant metastasis and local recurrence to be indepen-
dent risk factors for a shorter OS after recurrence  [6] . Fur-
thermore, in a recent report of 114 Japanese patients who 
experienced recurrence after RC, the detection of recur-
rence after 1 year was a positive independent predictor of 
OS after recurrence (HR 0.58, p = 0.021)  [5] . Differences 
in patient inclusion criteria, patient characteristics, fol-
low-up schemes, and patterns of recurrences may have 
accounted for this discrepancy. Nevertheless, our data 
confirms that the median time from RC to disease recur-
rence is usually <12 months (the median time to recur-
rence was 10.9 months in our study).
 A further important finding of the present study is 
that positive lymph nodes, an age greater than 74 years, 
and a positive STSM at RC are independent predictors of 
OS after recurrence ( table 3 ). This is in agreement with 
the current literature  [4, 6] . The results of the above men-
tioned Japanese single-center study point out that an age 
over 60 years has a significant detrimental influence on 
survival after disease recurrence  [5] . Positive lymph node 
status was not faced as a separate variable against lymph 
node negative status in the study by Mitra et al.  [6] , but 
lymph node density >10% was significantly associated 
with a worse OS after recurrence (p = 0.001).
 Retrospective studies suggest that the ASA score is a 
predictor of 90-day mortality, and the CCI and ACE-27 
are predictors of cancer-independent mortality in pa-
tients after RC of UCB  [9, 10] . In a retrospective study 
of Novotny et al. [13] consisting of 70 RC patients with 
an ASA score of 3 and an increased age ( ≥ 75), a regular 
recurrence-free survival but a decreased cancer-inde-
pendent mortality were observed. In the present study 
assessing 4 different comorbidity indices, only the CCI 
was predictive of the OS after disease recurrence. Study 
patients with CCI >2 had, after 6 and 12 months, can-
cer-specific mortality at higher rates of 18.5 and 14.1%, 
respectively, in contrast to patients with a CCI of 0–2. 
In addition, the integration of the dichotomized CCI 
in our multivariable model was able to increase the PA 
significantly.
 The present retrospective study had certain limitations 
that must be considered when interpreting its findings. 
Firstly, the assessment of the comorbidity scores at the 
time of RC must be respected. The median time between 
RC and recurrence was relatively short at 10.9 months; 
therefore, a significant change in comorbidity values at 
the time of recurrence would not be expected. Secondly, 
our analysis also could not be adjusted for the influence 
of the kind of therapy after recurrence. It is possible that 
healthier patients received more aggressive salvage ther-
apy. Thirdly, no information regarding the number of 
distant or local recurrences or the symptoms at the time 
of recurrence was available. Nakagawa et al.  [5] demon-
strated that the number of metastatic organs at recur-
rence was an independent predictor of OS after RC (HR 
2.16, p = 0.006).
 Our data suggest that more ill patients (CCI >2) show 
a significantly shorter OS after recurrence than their 
healthier counterparts (CCI  ≤ 2). An explanation for this 
reduced OS after recurrence could be that these patients 
do not get the same aggressive therapy as healthier pa-
tients. We therefore feel that these patients with recur-
rence after RC should be discussed in an interdisciplinary 
tumor board review in the same way as their healthier 
counterparts to offer them the best possible care consider-
ing their renal function, performance status, and worse 
outcomes after recurrence. In addition, the reduced sur-
vival of patients with a CCI >2 could be explained by a dif-
ferent tumor microenvironment, an impaired immune 
response, and/or a different metastatic cluster. Further re-
search could be helpful to understand the different tumor 
microenvironment, tumor immunology, and metastatic 
cluster in individuals with several comorbidities in order 
to translate this knowledge into therapeutic strategies for 
the patients.
 In conclusion, we present the first study that shows 
that comorbidity is an important predictor of OS after 
disease recurrence in patients undergoing RC for UCB. 
The dichotomized CCI independently predicted OS, 
along with age, lymph node metastasis, and positive sur-
gical margins. Specifically, patients with higher CCI 
scores are at a higher risk of dying from their recurrent 
disease. We recognize that more studies are necessary to 
confirm our findings and help to evaluate the full impact 
of comorbidity on survival. Finding more predictive sur-
vival measures such as comorbidity may help to assess 
patients at a higher risk for poorer survival and to iden-
tify candidates for additional salvage therapeutic strate-
gies and clinical trials.
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